Sweden's iZafe Group Q4 net sales rise on recurring license revenues

iZafe AB

16/02/2026 07:40

Overview

Swedish life science firm's Q4 net sales rose to 2,435 TSEK, driven by recurring license revenues

Q4 operating profit improved to -5,714 TSEK, reflecting strategic investments and Dutch consolidation

Company entered distribution agreements in Iceland and Norway for Dosell device

Outlook

Company forecasts 2026 ARR to reach SEK 22.5 mln, up 125% from start of year

iZafe Group aims to expand customer base and increase penetration in 2026

Company sees strategic value in potential Swedish framework agreement

Result Drivers

RECURRING REVENUES - Shift to a business model focused on recurring license revenues, with no hardware sales in Q4

DUTCH CONSOLIDATION - Consolidation of Dutch operations contributed to net sales and strengthened recurring revenue base

NORDIC EXPANSION - Distribution agreements in Iceland and Norway for Dosell device, expanding Nordic presence

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 2.44 mln
Q4 Adjusted EPS
-SEK 0.01
Q4 Operating Profit
-SEK 5.71 mln


Analyst Coverage

Wall Street's median 12-month price target for iZafe Group AB is SEK0.28, about 30% below its February 13 closing price of SEK0.40

Press Release: ID:nMFN1WsMPh

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)